Background: Bronchial thermoplasty (BT) is a rapidly emerging bronchoscopic treatment for patients with moderate-to-severe asthma. Different sedation strategies are currently used, ranging from mild midazolam sedation to general anesthesia requiring tracheal intubation. Objectives: The aim of this study was to assess the feasibility, safety, and both patients' and bronchoscopists' satisfaction with propofol and remifentanil sedation administered by specialized sedation anesthesiology nurses during BT in severe asthma patients. Methods: A prospective observational cohort study in BT-treated severe asthma patients of the TASMA trial was designed. Patients were asked to rate their overall BT procedure satisfaction and tolerance with propofol/remifentanil sedation using a visual analogue scale (VAS) ranging from 0 to 10. Similarly, bronchoscopists were asked to rate patient cooperation and tolerance. Sedation-associated adverse events and the number of BT activations were recorded. Results: Thirty-two BT procedures in 13 severe asthma patients were performed under moderate target-controlled infusion (TCI) propofol/remifentanil sedation. Patients' median VAS scores were as follows: overall satisfaction 9.6 (interquartile range [IQR] 8.5-10.0), dyspnea 0.0 (IQR 0.0-0.6), pain 0.1 (IQR 0.0-1.0), cough 0.5 (IQR 0.0-2.1), and anxiety 0.1 (IQR 0.0-0.7). Bronchoscopists' median VAS scores were as follows: overall patient cooperation 9.1 (IQR 8.5-9.6), dyspnea 0.3 (IQR 0.0-0.9), pain 0.2 (IQR 0.0-1.3), cough 1.2 (IQR 0.7-2.0), and discomfort 0.6 (IQR 0.3-1.5). All patients were willing to undergo the procedure again and would recommend this form of sedation to their best friend. One case of conversion to general anesthesia occurred and no serious adverse events were reported. Conclusions: Moderate sedation with propofol and remifentanil TCI provided by specialized sedation anesthesiology nurses is feasible and safe and results in high satisfaction rates of both patients and bronchoscopists.

Keywords:
Bronchial thermoplasty, Sedation, Propofol, Asthma, Bronchoscopy
1.
Pavord ID, et al: Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007;176:1185-1191.
2.
Castro M, et al: Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010;181:116-124.
3.
Cox G, et al: Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007;356:1327-1337.
4.
Pretolani M, et al: Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am J Respir Crit Care Med 2014;190:1452-1454.
5.
Miller JD, et al: A prospective feasibility study of bronchial thermoplasty in the human airway. Chest 2005;127:1999-2006.
6.
Cox PG, et al: Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J 2004;24:659-663.
7.
Martin L, Mayse ML, Rubin AS, Lampron N, Simof M, Duhamel D, Musani AI, Yung RC, Mehta AC: Clinical pearls for bronchial thermoplasty. J Bronchol 2007;14:115-123.
8.
Lee JA, Rowen DW, Rose DD: Bronchial thermoplasty: a novel treatment for severe asthma requiring monitored anesthesia care. AANA J 2011;79:480-483.
9.
Pawlowski J: Anesthetic considerations for interventional pulmonary procedures. Curr Opin Anaesthesiol 2013;26:6-12.
10.
Lo YL, et al: Feasibility of bispectral index-guided propofol infusion for flexible bronchoscopy sedation: a randomized controlled trial. PLoS One 2011;6:e27769.
11.
Clark G, et al: Titrated sedation with propofol or midazolam for flexible bronchoscopy: a randomised trial. Eur Respir J 2009;34:1277-1283.
12.
Chrissian AA, Bedi H: Bronchoscopist-directed continuous propofol infusion for targeting moderate sedation during endobronchial ultrasound bronchoscopy: a practical and effective protocol. J Bronchology Interv Pulmonol 2015;22:226-236.
13.
Tschopp JM, et al: Titrated sedation with propofol for medical thoracoscopy: a feasibility and safety study. Respiration 2011;82:451-457.
14.
Carmi U, et al: Propofol safety in bronchoscopy: prospective randomized trial using transcutaneous carbon dioxide tension monitoring. Respiration 2011;82:515-521.
15.
Bel EH, et al: Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011;66:910-917.
16.
Bousquet J, et al: Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926-938.
17.
Chernik DA, et al: Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol 1990;10:244-251.
18.
Langmack EL, et al: Serum lidocaine concentrations in asthmatics undergoing research bronchoscopy. Chest 2000;117:1055-1060.
19.
Revill SI, et al: The reliability of a linear analogue for evaluating pain. Anaesthesia 1976;31:1191-1198.
20.
Mavritsin LE, Lifshits NA: Complications in the fiber bronchoscopy of bronchial asthma patients (in Russian). Klin Med (Mosk) 1980;58:37-40.
21.
British Thoracic Society Bronchoscopy Guidelines Committee, a Subcommittee of the Standards of Care Committee of the British Thoracic Society: British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001;56(suppl 1):i1-i21.
22.
Wechsler ME, et al: Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013;132:1295-1302.
23.
Bonta PI, et al: Conscious sedation for EUS of the esophagus and stomach: a double-blind, randomized, controlled trial comparing midazolam with placebo. Gastrointest Endosc 2003;57:842-847.
24.
Goudra BG, et al: Anesthesia for advanced bronchoscopic procedures: state-of-the-art review. Lung 2015;193:453-465.
25.
Hwang J, et al: Comparison of alfetanil and ketamine in combination with propofol for patient-controlled sedation during fiberoptic bronchoscopy. Acta Anaesthesiol Scand 2005;49:1334-1338.
26.
American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists: Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002;96:1004-1017.
27.
DeWitt JM: Bispectral index monitoring for nurse-administered propofol sedation during upper endoscopic ultrasound: a prospective, randomized controlled trial. Dig Dis Sci 2008;53:2739-2745.
28.
Bosslet GT, et al: Nurse-administered propofol sedation: feasibility and safety in bronchoscopy. Respiration 2010;79:315-321.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.